Defensin human neutrophil peptide-2 - RELIEF THERAPEUTICS Holding

Drug Profile

Defensin human neutrophil peptide-2 - RELIEF THERAPEUTICS Holding

Alternative Names: Defensin HPN2

Latest Information Update: 12 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator mondoBIOTECH
  • Developer RELIEF THERAPEUTICS Holding
  • Class Peptides
  • Mechanism of Action Angiogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Vascular disorders

Most Recent Events

  • 16 Sep 2016 Defensin human neutrophil peptide-2 is available for licensing as of 16 Sep 2016.
  • 18 Jul 2016 THERAMetrics has merged with Relief Therapeutics forming RELIEF THERAPEUTICS Holding
  • 14 May 2014 mondoBIOTECH has patent protection for defensin human neutrophil peptide-2 in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top